Effectiveness of Lactobacillus rhamnosus (LGG) as an adjunct in the treatment of Enteric fever in Children. A Randomised Controlled Trial

Effectiveness of Lactobacillus rhamnosus (LGG) as an adjunct in the treatment of Enteric fever in Children. A Randomised Controlled Trial - LGG Lactobacillus rhamnosus GG

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048048

Enrollment

Registered

2022-08-18

Start date

2019-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

enteric fever

Interventions

The intervention group will receive Inj. Ceftriaxone (75 mg/kg/day in 2 divided doses for 7days) and LGG (probiotic) 3x109 CFU in a blinded powdered sachet once daily for 7days. The comparison group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children admitted to the paediatric ward with fever more than 100.4 degree celcius and Salmonella typhi or paratyphi grown in blood culture or Blood widal suggestive of Enteric fever. antigen titre more than 1in 160 or Four-fold rise in titre of blood widal witha minimum gap of 1 week between 2 samples.

Exclusion criteria

Exclusion criteria: Those who do not consent or assent Children who are critically ill Immuno-compromised children Children with enteric fever with no response to IV ceftriaxone even after 10 days of therapy

Design outcomes

Primary

Measure	Time frame
Defervescence in children with Enteric fever.	—

Secondary

Measure	Time frame
Resolution of toxemia in children with Enteric fever	—

Countries

Asia(except Japan)

Contacts

Public ContactAparna Jayaraman

ESIC MEDICAL COLLEGE AND PGIMSR MEDICAL COLLEGE

paedesic@gmail.com044-24748959

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026